Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage. Although gemcitabine (GEM) is commonly used as the first-line chemotherapy, many patients eventually develop resistance. This study aims to investigate the role of nicotinamide phosphoribosyltransferase (NAMPT) in mediating gemcitabine resistance in PDAC, with a focus on identifying potential therapeutic targets within the nicotinate and nicotinamide metabolic pathways.
Materials And Methods: We established the gemcitabine-resistant pancreatic cancer cell line BxPC-3-GR9 to simulate acquired resistance development. Subsequently, we conducted LC/MS metabolomics assays to identify altered metabolic pathways during gemcitabine resistance development. In addition, molecular and functional experiments targeting key enzymes in KEGG-enriched metabolic pathways to identify genes exhibiting significant changes. Mechanistically, transcriptome sequencing and molecular assays were employed to elucidate the regulatory mechanisms governing these target genes.
Results: Compared with parent BxPC-3 cell lines, significant alterations in the nicotinate and nicotinamide metabolic pathways were found in BxPC-3-GR9. Furthermore, nicotinamide was the only metabolite shared during the enrichment process; higher expression of NAMPT was also detected in gemcitabine-resistant cell lines. NAMPT knockdown increased gemcitabine sensitivity in gemcitabine-resistant cells, which was validated in inherently resistant cell lines. Transcriptome analysis and molecular experiments demonstrated that NAMPT regulates the p53 signaling pathway via CCND1/2, contributing to gemcitabine resistance.
Conclusion: These findings suggest that NAMPT could serve as a promising therapeutic target to overcome gemcitabine resistance in PDAC, laying the groundwork for future clinical investigations aimed at modulating nicotinate and nicotinamide metabolism to improve treatment outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0000000000002468 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nuclear cGAS mediated Replication Stress and Mitotic Catastrophe can Overcome Gemcitabine Resistance.
Cancer Lett
September 2025
Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA; Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR, USA.
Gemcitabine, a ribonucleotide reductase (RNR) inhibitor, is active in pancreatic ductal carcinoma (PDAC) patients, but unfortunately has a limited impact on long term outcomes. Gemcitabine induces nucleotide deficiency, DNA damage including single stranded DNA (ssDNA) and replication stress (RS). DNA damage can activate cyclic GMP-AMP synthase (cGAS), leading to genome instability, micronucleus generation, and immune activation.
View Article and Find Full Text PDFNatural lignan justicidin A-induced mitophagy as a targetable niche in bladder cancer.
Chem Biol Interact
September 2025
Department of Human Development and Family Studies, National Taiwan Normal University, Taipei 10610, Taiwan; Nutrition Science, School of Life Science, National Taiwan Normal University, Taipei 11677, Taiwan. Electronic address:
Accumulated dysfunctional mitochondria are involved in tumorigenesis, and it is conceivable that mitophagy, a selective form of autophagic degradation of mitochondria, plays a tumor-suppressive role. Our bioinformatics analysis identified lignan justicidin A (JA) as a potential mitophagy inducer. In HRAS-mutant human bladder cancer T24 cells, JA reduced population cell growth, changed mitochondrial membrane potential, and induced autophagy.
View Article and Find Full Text PDFTargeting ARPC1B Cancer Stem Cells to Sensitise Pancreatic Cancer to Gemcitabine Treatment.
Cell Prolif
September 2025
Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, China.
ARPC1B cancer stem cells (CSCs) in pancreatic cancer are identified as a subpopulation resistant to gemcitabine. In our study, drug repositioning, molecular docking, and surface plasmon resonance (SPR) technique jointly revealed that CK-636 can directly target ARPC1B protein with high affinity. In vitro cytotoxicity, ex vivo organoid cultures, in vivo xenograft and orthotopic gemcitabine-resistant pancreatic cancer model demonstrated that combination therapy of gemcitabine plus CK-636 showed a superior anti-tumor effect compared with gemcitabine monotherapy.
View Article and Find Full Text PDFNano-enabled repurposing of Benproperine phosphate enhances pancreatic Cancer chemotherapy through lethal autophagy arrest and immune activation.
J Control Release
September 2025
Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; MOE Joint International Research Laboratory of Pancreatic Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Gemcitabine-based chemotherapy remains a cornerstone in pancreatic cancer treatment, yet its efficacy is hindered by poor bioavailability and adaptive resistance mechanisms, such as autophagy. In this study, we developed a hyaluronic acid (HA) modified zeolitic imidazolate framework-8 (ZIF-8) drug-repurposing nanoplatform (HA/ZIF-8@BPP/Gem) against pancreatic cancer through the co-delivery of the antitussive benproperine phosphate (BPP) and gemcitabine (Gem). Using cell lines, patient-derived xenograft models, and orthotopic tumor models, we demonstrated that BPP and Gem, rapidly released from the nanoplatform in the acidic tumor microenvironment, exhibited synergistic cytotoxicity without causing significant biochemical abnormalities or organ toxicity.
View Article and Find Full Text PDFCUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.
PLoS One
September 2025
Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Gemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit. The present study aims to investigate the role of CUB domain-containing protein 1 (CDCP1) in mediating resistance to gemcitabine in UC cells. Gemcitabine-resistant T24 (T24-GR) cells exhibited downregulation of human equilibrative nucleoside transporter 1 and upregulation of cytidine deaminase, key regulators of gemcitabine metabolism, as well as increased CDCP1 expression.
View Article and Find Full Text PDF